NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

Case Solution

Reinhard Angelmar, Andrea Bieser
INSEAD ()

NICE (National Institute for Health and Clinical Excellence) opinions the fee effectiveness of drug treatments for the remedy of a couple of sclerosis (annual fee in keeping with affected person 10,000-18,000) and does now no longer authorize their use in the UK National Health Service. However, an settlement among the producers and the Department of Health is reached on an modern threat sharing scheme.

We don‘t have the case solution, but we pay up to $50 for yours!

  • Set a reminder to receive an email after your university‘s case study deadline.
  • Upload your case study solution. We will review it for quality.
  • Get your money via PayPal or to your bank account.